Skip to main content
INDV
NASDAQ Life Sciences

Indivior Projects Strong 2026 Profitability with 35% Adjusted EBITDA Growth and Resolves DOJ Matter

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$35.65
Mkt Cap
$4.481B
52W Low
$7.62
52W High
$38
52W Position info
368% above low
Off High info
6.2% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

INDV has more than doubled off its 52-week low of $7.62.

Summary

Indivior PLC announced strong full-year 2026 financial guidance, projecting significant Adjusted EBITDA growth and substantial operating expense savings, alongside an 11% increase in SUBLOCADE net revenue. The company also confirmed the full payment of its $295 million legacy U.S. Department of Justice obligation.


Key Events · Earnings and Guidance · INDV

  • Strong 2026 Financial Guidance

    Indivior projects full-year 2026 Adjusted EBITDA to grow by 35% to a midpoint of $555 million, with a 14 percentage point margin expansion to 48%.

  • SUBLOCADE Revenue Growth

    Net revenue for SUBLOCADE is expected to increase by 11% to a midpoint of $925 million in 2026, driven by accelerated dispense unit growth.

  • Significant Operating Expense Savings

    The company anticipates at least $150 million in annual non-GAAP operating expense savings in 2026, contributing to margin expansion.

  • Resolution of DOJ Obligation

    Indivior has fully paid the outstanding $295 million obligation related to a legacy U.S. Department of Justice matter, eliminating a major legal and financial risk.


Analysis · INDV · Life Sciences

Indivior PLC's 2026 financial guidance signals a robust outlook, driven by an expected 35% increase in Adjusted EBITDA and substantial operating expense reductions of at least $150 million. This profitability expansion is supported by an 11% projected growth in net revenue for SUBLOCADE, the company's key opioid use disorder treatment. The successful resolution of the $295 million legacy U.S. Department of Justice matter removes a significant financial and legal overhang, further de-risking the investment profile. These developments, coupled with the company's strategic "Accelerate" phase and inclusion in the S&P SmallCap 600 index, position Indivior for enhanced financial performance and increased investor confidence.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INDV was trading at $35.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $7.62 to $38.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INDV - Latest Insights

INDV
Nov 02, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $35.56
Real-time Price: $29.51 info
Change: -$6.05 (-17%) info
Market Cap: $6.174B info
INDV
Oct 29, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $35.25
Real-time Price: $29.51 info
Change: -$5.74 (-16%) info
Market Cap: $6.174B info
INDV
Oct 29, 2026, 8:14 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.51
Real-time Price: $29.51 info
Change: -$7.00 (-19%) info
Market Cap: $6.174B info
INDV
Oct 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $34.44
Real-time Price: $29.51 info
Change: -$4.93 (-14%) info
Market Cap: $6.174B info
INDV
Oct 29, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.44
Real-time Price: $29.51 info
Change: -$4.93 (-14%) info
Market Cap: $6.174B info